Revenue segments as reported by the company.

Sensor and other revenue

Hardware revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Collaborative research and development fee

Selling, general and administrative

Amortization of intangible assets

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

DexCom

DexCom, Inc. is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6 CGM System, DexCom G6 CGM System for Medicare, Software and Mobile apps. The company was founded by John F. Burd on May 1, 1999 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

DexCom excels in Q4 2022, eyes international expansion and margin growth

DexCom's Q4 2022 showcased robust financials, operational efficiency, and strategic advancements. The company is well-positioned for continued growth in 2023, with a focus on international expansion, marketing investments, and margin optimization.

DexCom excels in Q1, eyes international growth and market expansion

DexCom's strong Q1 performance and strategic initiatives position the company for sustained growth.
Balancing cost management, market expansion, and product enhancements will be crucial for future success.
Opportunities in new markets, user segments, and product improvements offer avenues for continued growth.
Overall, DexCom's focus on innovation and customer-centric strategies bode well for its long-term prospects.

DexCom reports robust Q2 earnings, eyes international expansion and new products

DexCom's Q2 performance reflects strong revenue growth and market momentum, supported by successful product launches and international expansion.
The company's focus on innovation, customer satisfaction, and cost reduction initiatives positions it well for continued success and market leadership.
While facing challenges in customer experience and product adoption, DexCom's strategic strengths and growth opportunities signal a promising outlook for the future.

DexCom achieves record Q3 performance and expands market leadership

DexCom's Q3 performance reflects strong revenue growth, operational efficiency, and strategic market expansion efforts, setting new records in financial metrics.
The company's strengths lie in market leadership, product innovation, and proactive market expansion strategies, supported by a strong brand and organizational culture.
While facing challenges in pricing strategies, timeline for revenue contributions, and distribution accessibility, DexCom is well-positioned to capitalize on opportunities in new markets and product launches.
Overall, DexCom's performance, strengths, and proactive approach to challenges and opportunities position it for sustained growth and market leadership in the medical devices sector.

DexCom excels in Q4 2023, eyes growth through strategic initiatives

DexCom's strong financial performance, product launches, and market expansions in 2023 set a solid foundation for future growth.
Strategic investments, competitive advantages, and a focus on margin progression position DexCom for continued success.
Challenges in reimbursement pathways and market penetration are being addressed, while opportunities in expanding coverage and product enhancements are being pursued.

DexCom excels in Q1 2024, eyes global expansion and innovation

DexCom's strong financial performance, strategic market expansions, and product innovations position the company for continued growth and success.
While facing challenges in market penetration and product adoption timelines, DexCom's focus on user experience and healthcare outcomes remains a key strength.
Opportunities lie in international market expansion, product differentiation, and leveraging sensor technology for improved patient care and business growth.

DexCom reports 15% revenue growth but lowers full-year guidance

DexCom faced challenges in customer additions and revenue per customer in the U.S. and below-expectation international performance. Despite this, they reported 15% revenue growth and lowered full-year revenue guidance to 11%-13% organic growth.

DexCom meets revenue targets, Stelo launch successful, challenges ahead

DexCom's Q3 performance met expectations with growth in key areas.
Strong market reception for Stelo presents revenue and growth opportunities.
Challenges exist in managing differing customer expectations and sensor performance.
Opportunities lie in expanding international markets and enhancing customer experiences.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered in San Diego, CA.

NEW YORK, NY / ACCESSWIRE / September 13, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ:DXCM) and certain of the Company's senior executives. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc.

DXCM STOCK ALERT: A Class Action is Pending Against DexCom, Inc. for Securities Fraud; Contact BFA Law before October 21 Court Deadline if You Lost Money

LOS ANGELES, CA / ACCESSWIRE / September 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against DexCom, Inc. ("DexCom" or "the Company") (NASDAQ:DXCM) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 8, 2024 and July 25, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 21, 2024.

DexCom Inc Is Being Sued For Possible Securities Fraud And The Schall Law Firm Urges Investors To Initiate Contact

NEW YORK, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ: DXCM) and certain of the Company's senior executives.

DXCM INVESTOR DEADLINE: DexCom, Inc. Investors that Lost Money are Reminded to Contact BFA Law by October 21 Court Deadline in Class Action Lawsuit (Nasdaq:DXCM)

RADNOR, PA / ACCESSWIRE / September 12, 2024 / The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against DexCom, Inc. ("DexCom") (NASDAQ:DXCM) on behalf of investors who purchased or otherwise acquired DexCom securities between January 8, 2024 to July 25, 2024, inclusive (the "Class Period") The lead plaintiff deadline is October 21, 2024. CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP: If you suffered DexCom losses, you may CLICK HERE or go to: https://www.ktmc.com/new-cases/dexcom-inc?utm_source=PR&utm_medium=link&utm_campaign=dxcm&mktm=r Please CLICK HERE to view our video or copy and paste this link into your browser: https://youtu.be/gzkLvw7x_7Y You can also contact attorney Jonathan Naji, Esq.

DXCM Shareholder Reminder: Kessler Topaz Meltzer & Check, LLP Reminds DexCom, Inc. Shareholders of Deadline in Securities Fraud Class Action Lawsuit

NEW YORK, NY / ACCESSWIRE / September 12, 2024 / If you suffered a loss on your DexCom, Inc. (NASDAQ:DXCM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/dexcom-inc-lawsuit-submission-form?prid=102282&wire=1 or contact Joseph E. Levi, Esq.

DexCom, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before October 21, 2024 to Discuss Your Rights - DXCM

NEW YORK, NY / ACCESSWIRE / September 12, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ:DXCM) and certain of the Company's senior executives. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc.

DXCM INVESTOR NOTICE: If You Invested in DexCom, Inc., Contact BFA Law Before Imminent October 21 Deadline in Securities Fraud Class Action Case

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In DexCom To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in DexCom between January 8, 2024 to July 25, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (Ext. 1310). [You may also click here for additional information] NEW YORK , Sept.

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of DexCom

LOS ANGELES, CA / ACCESSWIRE / September 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against DexCom, Inc. ("DexCom" or "the Company") (NASDAQ:DXCM) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 8, 2024 and July 25, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 21, 2024.

Stockholders Can Contact The Schall Law Firm About A Case Against DexCom, Inc. For Securities Law Violations

Investors have been bearish on DexCom's numbers all this past year. The opportunity in diabetes care, however, remains significant in the long run.

3 Reasons DexCom Looks Like a No-Brainer Buy Right Now

NEW YORK, Sept. 12, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of DexCom, Inc. (NASDAQ: DXCM).

Class Action Filed Against DexCom, Inc. (DXCM) Seeking Recovery for Investors - Contact The Gross Law Firm

NEW YORK, NY / ACCESSWIRE / September 11, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ:DXCM) and certain of the Company's senior executives. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc.

DXCM INVESTOR ALERT: If You Suffered Losses on Your DexCom, Inc. Investment, Contact BFA Law Before Upcoming October 21 Class Action Deadline

RADNOR, Pa. , Sept. 11, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com)  informs investors that a securities class action lawsuit has been filed against DexCom, Inc. ("DexCom") (NASDAQ: DXCM) on behalf of investors who purchased or otherwise acquired DexCom securities between January 8, 2024 to July 25, 2024, inclusive (the "Class Period")  The lead plaintiff deadline is October 21, 2024.

Kessler Topaz Meltzer & Check, LLP Reminds DXCM Investors of October 21, 2024 Deadline in Securities Fraud Class Action and Urges Investors with Losses to Contact the Firm

NEW YORK, NY / ACCESSWIRE / September 11, 2024 / If you suffered a loss on your DexCom, Inc. (NASDAQ:DXCM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/dexcom-inc-lawsuit-submission-form?prid=101951&wire=1 or contact Joseph E. Levi, Esq.

Shareholders that Lost Money on DexCom, Inc. (DXCM) Should Contact Levi & Korsinsky About Pending Class Action - DXCM

SAN FRANCISCO, CA / ACCESSWIRE / September 11, 2024 / Hagens Berman urges DexCom, Inc. (NASDAQ:DXCM) investors who suffered substantial losses to submit your losses now. The firm also encourages persons with knowledge who may be able to assist in the investigation to contact its attorneys.

DexCom (DXCM) Faces Investor Backlash After Disappointing Earnings Report - Hagens Berman

LOS ANGELES, CA / ACCESSWIRE / September 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against DexCom, Inc. ("DexCom" or "the Company") (NASDAQ:DXCM) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 8, 2024 and July 25, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 21, 2024.

DexCom Inc Is Being Sued For Possibly Committing Securities Fraud And The Schall Law Firm Urges Investors To Reach Out

NEW YORK, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ: DXCM) and certain of the Company's senior executives.

DXCM LAWSUIT NEWS: A Class Action Lawsuit has been Filed Against DexCom, Inc. for Securities Fraud; Contact BFA Law before October 21 Legal Deadline (Nasdaq:DXCM)

NEW YORK, NY / ACCESSWIRE / September 10, 2024 / If you suffered a loss on your DexCom, Inc. (NASDAQ:DXCM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/dexcom-inc-lawsuit-submission-form?prid=101759&wire=1 or contact Joseph E. Levi, Esq.

DexCom, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 21, 2024 to Discuss Your Rights – DXCM

Despite a recent 40% drop in DexCom's stock price, I remain optimistic about its long-term potential due to its strong market position and innovative pipeline. DexCom faces significant headwinds, including slower customer growth and increased competition, but remains well-positioned in the growing continuous glucose monitoring market. Execution risks and increased competition are notable concerns, but the company's addressable market and demand for diabetes management tools provide a compelling risk/reward opportunity.

DexCom's Drop Is Your Shot

NEW YORK, Sept. 10, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of DexCom, Inc. (NASDAQ: DXCM).

DexCom, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before October 21, 2024 to Discuss Your Rights – DXCM

RADNOR, Pa., Sept. 10, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of California against DexCom, Inc. (“DexCom”) (NASDAQ: DXCM) on behalf of investors who purchased or otherwise acquired DexCom securities between January 8, 2024 to July 25, 2024, inclusive (the “Class Period”) The lead plaintiff deadline is October 21, 2024.

Class Action Reminder for NASDAQ: DXCM: Kessler Topaz Meltzer & Check, LLP Reminds DexCom, Inc. Investors of Securities Fraud Class Action Lawsuit

SCOTTSDALE, Ariz.--(BUSINESS WIRE)--UpScriptHealth, the leading direct-to-patient telehealth company providing new distribution channels for pharmaceutical and medical device brands, announced today that following the success of its GetDexcomRx.com pilot program it is expanding its partnership with Dexcom, the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes. UpScriptHealth now powers telehealth consultations for people with diabetes who visit Dexcom.com.

Direct-to-Patient Telemedicine Company UpScriptHealth Increases Access to Continuous Glucose Monitoring (CGM) For People with Diabetes Through Expanded Strategic Partnership with Dexcom

NEW YORK, NY / ACCESSWIRE / September 10, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ:DXCM) and certain of the Company's senior executives. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc.

DXCM DEADLINE NOTICE: Lose Money in Your DexCom, Inc. Investment? Contact BFA Law before October 21 Deadline in Securities Fraud Class Action

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, today announced the Dexcom G6 Continuous Glucose Monitoring (CGM) System is being worn by astronauts in space as part of the Polaris Dawn mission, which launched this morning and aims to better understand the effects of spaceflight on human health. While in orbit, the Polaris Dawn crew will conduct scientific research designed to advance both human heal.

Dexcom CGM Worn in Outer Space as Part of First-of-its-Kind Polaris Dawn Mission

NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between January 8, 2024 and July 25, 2024, both dates inclusive (the “Class Period”), of the important October 21, 2024 lead plaintiff deadline in the securities class action.

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages DexCom, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – DXCM

NEW YORK, NY / ACCESSWIRE / September 9, 2024 / If you suffered a loss on your DexCom, Inc. (NASDAQ:DXCM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/dexcom-inc-lawsuit-submission-form?prid=101412&wire=1 or contact Joseph E. Levi, Esq.

News for DexCom Stock (DXCM)